__NUXT_JSONP__("/drugs/Paricalcitol", (function(a,b,c,d,e,f,g,h,i){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[{brand:a,indication:b,manufacturer:"Dr. Reddy's Laboratories, Inc.",splSetId:"07e49b4e-5a6d-66aa-97c8-7ca582d44771"},{brand:a,indication:"1 INDICATIONS AND USAGE Paricalcitol is a vitamin D analog indicated in adults and pediatric patients 10 years and older for the prevention and treatment of secondary hyperparathyroidism associated with: Chronic kidney disease (CKD) Stages 3 and 4 ( 1.1 ). CKD Stage 5 in patients on hemodialysis or peritoneal dialysis ( 1.2 ). 1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol capsules are indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. 1.2 Chronic Kidney Disease Stage 5 Paricalcitol capsules are indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD).",manufacturer:"Zydus Pharmaceuticals USA Inc",splSetId:"0f2e6d12-9be9-500d-6ac6-920e0c7c14b1"},{brand:a,indication:"1 INDICATIONS & USAGE 1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (Paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Chronic Kidney Disease Stage 5 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD). Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (Paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Paricalcitol is a vitamin D analog indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with: Chronic kidney disease (CKD) Stages 3 and 4 (1.1). CKD Stage 5 in patients on hemodialysis or peritoneal dialysis (1.2).",manufacturer:"MARKSANS PHARMA LIMITED",splSetId:"0fbaff52-f08f-42b7-8e46-c7214112901a"},{brand:c,indication:"1 INDICATIONS AND USAGE ZEMPLAR is a vitamin D analog indicated in adults and pediatric patients 10 years and older for the prevention and treatment of secondary hyperparathyroidism associated with: Chronic kidney disease (CKD) Stages 3 and 4 ( 1.1 ). CKD Stage 5 in patients on hemodialysis or peritoneal dialysis ( 1.2 ). 1.1 Chronic Kidney Disease Stages 3 and 4 ZEMPLAR capsules are indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. 1.2 Chronic Kidney Disease Stage 5 ZEMPLAR capsules are indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD).",manufacturer:f,splSetId:"1b27c026-2d60-47b4-2a9c-ded1818f21b5"},{brand:a,indication:d,manufacturer:g,splSetId:"22a0d467-9881-458f-8b1c-1186feb96ee4"},{brand:a,indication:"1 INDICATIONS AND USAGE Paricalcitol Injection is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. Paricalcitol Injection is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis.",manufacturer:"Accord Healthcare, Inc.",splSetId:"2b7c7587-2042-0d9c-e054-00144ff88e88"},{brand:a,indication:b,manufacturer:"Akorn, Inc.",splSetId:"3638a75b-eeda-4fa4-80c3-a659690ac464"},{brand:a,indication:b,manufacturer:"Mylan Institutional LLC",splSetId:"37bba708-1606-4edb-aa56-89b34c44d246"},{brand:a,indication:"1 INDICATIONS AND USAGE Paricalcitol Injection is an active vitamin D 2 analogue indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 5. Paricalcitol Injection is an active vitamin D 2 analog indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease Stage 5. ( 1 )",manufacturer:"West-Ward Pharmaceuticals Corp",splSetId:"4db985c4-3ba2-4967-898b-35af77f150de"},{brand:a,indication:d,manufacturer:g,splSetId:"52ca3d88-e85d-44a9-8aa7-eb25a8a73f6f"},{brand:a,indication:"1 INDICATIONS AND USAGE Paricalcitol is a vitamin D analog indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with: Chronic kidney disease (CKD) Stages 3 and 4 (1.1) . CKD Stage 5 in patients on hemodialysis or peritoneal dialysis (1.2) . 1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Chronic Kidney Disease Stage 5 Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD). Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.",manufacturer:"Aurobindo Pharma Limited",splSetId:"59738576-3494-4d72-98d2-6904a3778081"},{brand:e,indication:b,manufacturer:"AuroMedics Pharma LLC",splSetId:"6937c596-9ca4-480e-9090-b9d8a3c271c8"},{brand:c,indication:"1 INDICATIONS AND USAGE ZEMPLAR is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. ZEMPLAR is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis ( 1 ).",manufacturer:f,splSetId:"7259652f-81bc-4ad1-bba5-d01f9fac1b80"},{brand:a,indication:d,manufacturer:"Bionpharma Inc.",splSetId:"755476e5-62a2-4f01-92a3-307e192ad42c"},{brand:a,indication:"1 INDICATIONS AND USAGE Paricalcitol injection is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. Paricalcitol injection is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis. ( 1 )",manufacturer:h,splSetId:"8e0b016c-4bda-487e-b525-63abfb772761"},{brand:a,indication:"1 INDICATIONS AND USAGE Paricalcitol is a vitamin D analog indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with. · Chronic kidney disease (CKD) Stages 3 and 4 ( 1.1 ). · CKD Stage 5 in patients on hemodialysis or peritoneal dialysis ( 1.2 ). 1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Chronic Kidney Disease Stage 5 Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD). Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information",manufacturer:"Dr. Reddy's Laboratories Limited",splSetId:"aa1a80e9-8778-a03e-5d53-d4b6a6363169"},{brand:a,indication:"1 INDICATIONS AND USAGE Paricalcitol Injection is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. Paricalcitol Injection is a vitamin D 2 analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis ( 1 ).",manufacturer:"Hospira, Inc.",splSetId:"b2e4eaa9-bf4d-4fe8-ab2e-d2b1a3a555ca"},{brand:a,indication:"1 INDICATIONS AND USAGE Paricalcitol capsules are a vitamin D analog indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with: Chronic kidney disease (CKD) Stages 3 and 4 (1.1) . CKD Stage 5 in patients on hemodialysis or peritoneal dialysis (1.2) . 1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Chronic Kidney Disease Stage 5 Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD). Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.",manufacturer:h,splSetId:"cd937aab-6ed2-44ef-b91e-82738997ed10"},{brand:e,indication:"1 INDICATIONS AND USAGE Paricalcitol is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 ( 1.1 ). CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD) ( 1.2 ). 1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol Capsules are indicated for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. 1.2 Chronic Kidney Disease Stage 5 Paricalcitol Capsules are indicated for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD).",manufacturer:"Lotus Pharmaceutical Co., Ltd. Nantou Plant",splSetId:"f4a3ff3a-fb49-4901-afdc-92723d7902ee"}],id:a,nciThesaurus:{casRegistry:"131918-61-1",chebiId:"CHEBI:7931",chemicalFormula:"C27H44O3",definition:"A synthetic noncalcemic, nonphosphatemic vitamin D analogue.  Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone (PTH) levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors, resulting in tumor cell apoptosis and tumor cell differentiation into normal phenotypes.",fdaUniiCode:"6702D36OG5",identifier:"C38693",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C39713"],synonyms:["(7e,22e)-19-Nor-9,10-Secoergosta-5,7,22-Triene-1Alpha,3Beta,25-Triol","Compound 49510",e,a,c,"paricalcitol"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FParicalcitol",extension:".json",createdAt:i,updatedAt:i}}],fetch:{},mutations:void 0}}("Paricalcitol","1 INDICATIONS AND USAGE Paricalcitol injection is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. Paricalcitol injection is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis ( 1 ).","Zemplar","1 INDICATIONS AND USAGE Paricalcitol is a vitamin D analog indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with: Chronic kidney disease (CKD) Stages 3 and 4 ( 1.1 ). CKD Stage 5 in patients on hemodialysis or peritoneal dialysis ( 1.2 ). 1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Chronic Kidney Disease Stage 5 Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD). Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.","PARICALCITOL","AbbVie Inc.","Bryant Ranch Prepack","Amneal Pharmaceuticals LLC","2021-10-30T13:39:37.513Z")));